ANI PHARMACEUTICALS, INC Business Combination, Acquisition Related Costs
ANI PHARMACEUTICALS, INC (ANIP) reported Business Combination, Acquisition Related Costs of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2016-02-23
- ANI PHARMACEUTICALS, INC business combination, acquisition related costs for the quarter ending 2013-12-31 was $0.00.
- ANI PHARMACEUTICALS, INC business combination, acquisition related costs for the quarter ending 2013-09-30 was $500.00K.
- ANI PHARMACEUTICALS, INC business combination, acquisition related costs for the quarter ending 2013-06-30 was $5.50M.
- ANI PHARMACEUTICALS, INC business combination, acquisition related costs for the quarter ending 2013-03-31 was $100.00K.
- ANI PHARMACEUTICALS, INC business combination, acquisition related costs for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- ANI PHARMACEUTICALS, INC business combination, acquisition related costs for fiscal 2013 was $6.20M, a 588.89% increase from fiscal 2012.
- ANI PHARMACEUTICALS, INC business combination, acquisition related costs for fiscal 2012 was $900.00K.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 6 month as first filed | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 9 month as first filed | Business Combination, Acquisition Related Costs 12 month | Business Combination, Acquisition Related Costs 12 month as first filed | Business Combination, Acquisition Related Costs 24 month |
|---|---|---|---|---|---|---|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-02-23 | |||||||
| 2014-03-31 | $7.10M 10-Q · filed 2014-05-12 | |||||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $500.00K derived: sum of 2 quarters · filed 2016-02-23 | $6.00M derived: sum of 3 quarters · filed 2016-02-23 | $6.20M 10-K · filed 2016-02-23 | $7.10M 10-K · filed 2014-02-28 | |||
| 2013-09-30 | $500.00K 10-Q · filed 2014-11-10 | $6.00M derived: sum of 2 quarters · filed 2014-11-10 | $6.20M 10-Q · filed 2014-11-10 | $6.16M 10-Q · filed 2013-11-07 | ||||
| 2013-06-30 | $5.50M 10-Q · filed 2014-08-07 | $5.70M 10-Q · filed 2014-08-07 | $5.66M 10-Q · filed 2013-08-09 | |||||
| 2013-03-31 | $100.00K 10-Q · filed 2014-05-12 | |||||||
| 2012-12-31 | $900.00K 10-K · filed 2014-02-28 | $928.70K 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |